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Combined NMR and MS 
analysis for tracer based 
metabolic flux experiments 
 
Mei Chong[b], Anusha Jayaraman[c], Silvia Marin[c], 
Vitaly Selivanov[c], Pedro R. de Atauri Carulla[c], 
Daniel A. Tennant[d], Marta Cascante[c], Ulrich L. 
Günther[b], Christian Ludwig*[a] 
Abstract: Cellular metabolism in mammalian cells represents an 
emerging challenge for analytical chemistry in the context of current 
biomedical research. Mass spectrometry (MS) and Nuclear Magnetic 
Resonance (NMR) spectroscopy in connection with computational 
tools have been used to study metabolism in cells. 
Compartmentalization of metabolism complicates the interpretation of 
stable isotope patterns in mammalian cells owing to the 
superimposition of different pathways contributing to the same pool of 
analytes in whole cell extracts. This indicates a need for a model-free 
approach to interpret such tracer-based data. MS and NMR provide 
complementary analytical information for metabolites with partial label 
incorporation in different positions. Here we present an approach that 
first simulates 13C-multiplets in NMR spectra and utilizes mass 
increments to obtain long-range information.  In a second step the 
combined information is utilized to derive isotopomer distributions for 
key metabolites. This is a first rigorous analytical and computational 
approach for a model-free analysis of metabolic flux data applicable 
to mammalian cells. 
With every change in the phenotype of a cell or tissue, a 
supportive or compensatory change in metabolism is required. It 
therefore comes as no surprise that most, if not all, diseases are 
associated with, or in some cases driven by, changes in 
metabolism[1–3]. However, metabolic networks in mammalian cells 
are complex[4–7]. Despite existing models[8,9] our understanding of 
the mammalian metabolic network is still incomplete. Specific 
metabolic pathways can be studied using tracer-based 
approaches after exposing cells or tissues to a metabolic 
precursor enriched with one or more stable isotopes[10–12] (e.g. 
13C-labelled glucose or glutamine). When the enriched metabolic 
precursors are metabolized label is incorporated into various 
metabolites, giving rise to a potentially large number of 
isotopomers[13–16]. The isotopomer distributions depend on the 
metabolic pathways through which the labelled precursors have 
been metabolized. For instance, for cells grown in the presence 
of [1,2-13C2]-D-glucose an isotopomer analysis for C4 of 
glutamate can be used to infer flux through pyruvate 
dehydrogenase (PDH) into the TCA cycle (also known as the 
Krebs cycle). 13C-observed NMR spectra provide information on 
isotopomer compositions, as multiplet structures alter with 13C 
label incorporation in metabolites[17,18]. This is however limited to 
large concentrations of metabolites even when 13C optimized 
NMR probes are used. 1H-13C-Heteronuclear Single Quantum 
Coherence (HSQC) spectra are substantially more sensitive 
although limited to proton bearing carbons., For this HSQC 
spectra need to be collected with a high number of increments to 
observe JCC couplings, which is now best achieved using non-
uniformly samples spectra (NUS). For example, much of the 
activity of the TCA cycle can be derived from multiplet patterns in 
molecules such as glutamate which reflect the mechanisms how 
the molecule was produced. This can either be through entry of 
pyruvate into the TCA via pyruvate dehydrogenase (PDH), or 
alternatively via pyruvate carboxylase (PC), but can also be a 
transamination product of glutamine or protein degradation. 
Additional information on isotopomers can be derived from 
mass spectrometry[19,20], which yields mass increments rather 
than atom specific information. This provides crucial information 
in conjunction with the aforementioned NMR analysis which is 
complementary to the site-specific NMR information[21,22]. Here we 
present an algorithm for a bias-free determination of isotopomer 
compositions. The approach consists of two steps. The first step 
is to simulate the NMR spectrum for the different isotopomers. An 
NMR signal is only observed if at least one position is 13C-labelled; 
in MS-terms this means that an m+1 or higher-labelled molecule 
is observed. 
Isotopomer analysis is split into two parts as shown in Figure 
1. First NMR multiplets are simulated using the pyGamma[23] 
library. Because the HSQC NMR spectra were acquired using 
echo/anti-echo coherence selection, development of carbon-
carbon couplings is not zero in the first increment. To minimise 
computational time, the effect of the non-zero JCC contribution is 
mimicked by the simulation of a 13C spin-echo before the 
simulation of the 13C free induction decay. This procedure 
produces good results for molecules in the absence of strongly 
coupled carbon-carbon spin systems, an assumption that is valid 
for all multiplets derived from 13C-labelled glucose. The result of 
this simulation is shown in Figure 2 for glutamate C2 in MCF7 
cells that were labelled with [1,2-13C] glucose. Multiplets for other 
metabolites are shown in Figures S1-S5. This analysis simulates 
the sum of sub spectra arising from the label incorporation in 
adjacent carbons. For example, the simulation of glutamate C2 
simulates contributions of spectra arising from the JC2C1, JC2C3, 
JC2C1C3 couplings and of the uncoupled spectrum. This analysis 
yields local 13C-labelling pattern for C2, disregarding the 12C-
contribution of C2 which is not observed in NMR spectra as well 
as remote 13C-incorporations. The main focus of this algorithm is 
on the relative multiplet contributions which is independent of the 
polarisation transfer function in HSQC spectra and therefore 
independent of the JCH coupling constant. 
In a second step the theoretical MS isotopologues, the HSQC 
multiplet percentages for all NMR visible carbon nuclei and the 
absolute 13C enrichment percentages per carbon (1D NMR data) 
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are simulated using a proposed isotopomer distribution (Fig. S6). 
This simulated NMR/MS data is then fitted to the experimental 
values using a least squares minimisation procedure by varying 
the proposed isotopomer distribution percentages. While at the 
beginning of the fitting procedure (without choosing which 
isotopomers are most likely present), the 1D NMR data are quite 
important, because the addition of per carbon 13C percentages 
guides the fitting algorithm by reducing the amount of local 
minima; at latter stages of the fitting procedure (i.e. after the final 
set of isotopomers has been chosen based on all the data), it is 
beneficial to finalise the fit using just the NMR multiplet 
percentages and the MS isotopologue data as the 1D NMR data 
because of spectral congestion. 
 
Figure 1. Schematic representation of model-free isotopomer analysis. After 
samples have been labelled using 13C-enriched metabolic precursors, the cells 
are harvested and extracted using a modified Bligh-Dyer procedure. Each 
sample is then split before drying, where 90% are further prepared for NMR 
analysis and 10% for MS. 2D-1H,13C-HSQC spectra are acquired, mass spectra 
are acquired after derivatisation. In a first step, HSQC signals are simulated 
considering contributions of the possible JCC-couplings contributing to the 
multiplet (c.f. Fig. 2). In a second step, the isotopomer composition is optimised 
for each metabolite to fit the relative composition of each multiplet together with 
the MIDs from the mass spectra. At no point during this analysis any 
assumptions are made about metabolic activity or pathways.  
The analysis of metabolism in mammalian cells is complicated 
by the fact that several metabolic mechanisms contribute to the 
same metabolite pools. This is exacerbated in tracer-based 
experiments where isotopomers arise from label incorporation in 
different processes. In prokaryotic systems[24,25] computational 
metabolic flux is usually sufficient to quantify contributions from 
individual pathways. In eukaryotic cells mechanisms are more 
complex and therefore a model-free approach is desirable. Here 
we show that a model-free approach that simultaneously 
analyses signal multiplets in 1H-13C-HSQC NMR spectra and 
MIDs derived from GC-MS spectra, without assuming a metabolic 
model, yields site-specific isotopomer information for a range of 
key metabolites. 
The process of this analysis is depicted in Fig. 1. The analysis 
is carried out in two steps, first by simulating the relative 
contributions of different coupling patterns to each multiplet. It is 
important to recognize that NMR by nature observes m+1 and 
above isotopomers only, because the 12C-nucleus is not 
observable. Hence relative label incorporations in relation to the 
observed atom are obtained in this step. In the second step, this 
NMR information is combined between different atoms of one 
molecule and with the MIDs from MS. At no point during this 
analysis any assumptions are made about metabolic activity or 
pathways. Therefore, this approach represents a model-free 
isotopomer analysis of metabolic tracer data.  
 
Figure 2. (A) Multiplet analysis of glutamate C2.  Panel A depicts the 
deconvolution of the different constituting parts of the C2 multiplet of glutamate. 
The multiplet basically consists of 4 different components: glutamate with (i) C2 
labelled (amber), (ii) C1 and C2 labelled simultaneously (blue), (iii) C2 and C3 
labelled simultaneously (green) and (iv) C2, C1 and C3 labelled simultaneously 
(black). (B) shows the experimental spectrum of glutamate C2 in black and the 
fitted multiplet in grey. Overlap with the C2 or glutamine does not impair the 
analysis. (See supporting information for more detailed information on the 
implementation of multiplet analysis) 
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Fig. 2 shows an exemplary analysis for glutamate C2 where 
contributions of JC1C2, JC1C2C3, JC2C3 are considered in addition to 
C2 only labelled glutamate. 2JCC couplings are not resolved and 
therefore don’t contribute to distinguishable signals in this 
spectrum. Therefore, the information extracted from this type of 
analysis is local in nature. As seen in Fig. 2B (and in Figs S1-S5) 
good simulations can be obtained for the signals of several 
metabolites, including lactate, alanine, glutamate and aspartate. 
These are key reporters for central metabolism.  Fig 3. Illustrates 
the quality of fit obtained for several metabolites in the MCF7 cells 
used for this analysis. The analysis of a model mixture composed 
of [1-13C], [1,2-13C] and [U-13C] glucose is shown in Fig. S7.  
 
Figure 3. Quality of data analysis. Percentage contribution of multiplets and 
MIDs are reported for a simulation of the isotopomers of pyruvate, lactate, 
alanine, glutamate and aspartate. Data was used from 3 replicate samples of 
labelled MCF7 cells.   
Considering the orthogonal nature of the two analytical 
techniques used in this approach, the question arises whether the 
two independent data sets lead to the same quantitative 
conclusions. Fig. 3 demonstrates that the NMR & MS data sets 
are highly consistent with each other, as supported by virtually 
perfect agreement between simulated and experimental data with 
a correlation coefficient of 99.97%. The combination of 2D-HSQC 
NMR and MS data together with [1,2-13C] or [U-13C] is unique 
because of the 1.07% natural abundance of 13C. Since most of 
the singly labelled (i.e. no J coupling contributions) signals contain 
considerable contributions from unlabelled material, the area of 
highest accuracy for 2D-HSQC NMR data is between 1 and 10 % 
label incorporation. This is in contrast to other homonuclear NMR 
approaches such as 2D-1H,1H-TOCSY spectra or MS data which 
have their lowest accuracy between 1 and 10%. It is the 
combination of these two complementary techniques that enables 
a precise and accurate determination over the entire potential 
labelling percentages range. 
This type of analysis allows for a series of important 
conclusions. For example, as shown in Fig. 4, lactate and alanine 
show characteristic labelling patterns in cells labelled with [1,2-
13C2] glucose. If entirely produced by glycolysis C2 and C3 will 
always be jointly labelled and should hence show equal label 
incorporation. However, in the presence of pentose phosphate 
pathway activity, where the C1 of glucose is removed in the first 
step, label incorporation will be different in these positions[26,27]. In 
this analysis, we observe approx. 3.5% PPP contribution 
observed for lactate and pyruvate, whereas glycolysis contributes 
22.5-23.5% to the label incorporation. Given that the glucose 
molecule is split into two parts, with one unlabelled for [1,2-13C] 
glucose, this is equivalent to 7% PPP, and 45% glycolytic activity, 
respectively. Results from the isotopomer analysis are depicted 
in Fig. 1 for lactate, alanine, glutamate and aspartate. 
 
Figure 4. Tracing central metabolism using [1,2-13C] glucose. Panel A: Glucose 
is primarily converted to pyruvate, either via glycolysis or via the pentose 
phosphate pathway (including both, the oxidative and the non-oxidative part). 
Depending on the pathway, either [2,3-13C] or [3-13C] pyruvate is produced. 
Read-out surrogates for glycolysis vs PPP usage are lactate, which is 
exclusively produced in the cytosol of mammalian cells and alanine, which can 
be produced both in the cytosol as well as mitochondria. Panel B: Pyruvate can 
then enter the citric acid cycle via two entry points. It can either be converted to 
acetyl-CoA by pyruvate dehydrogenase and then be condensated with 
oxaloacetate to form citrate, or it can be carboxylated to form oxaloacetate 
which then can be transformed into citrate or other molecules such as aspartate. 
Again, the labelling patterns in reporter molecules such as glutamate or 
aspartate are depending on the metabolic pathways used to produce these 
molecules. 
Similarly, the entry point for pyruvate into the TCA cycle, 
through PDH or alternatively through the anaplerotic PC, 
generates different isotopomers (in Fig. 4B magenta for PC, and 
green for PDH). Isotopomers of TCA read-out molecules such as 
glutamate, malate and aspartate will inform on the presence and 
relative amount of PC activity. [4,5-13C2] glutamate is produced 
through the activity of PDH on pyruvate, while [2,3-13C2] glutamate 
is produced by PC activity. The [1,2-13C2] and [3,4-13C2] 
isotopomers of aspartate are also observed as a result of PDH, 
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while PC activity produces [2,3-13C2] aspartate.  This type of 
analysis has recently been used in three reports to identify relative 
contributions of different metabolic pathways[28–30].  
In the future, this approach may provide an avenue to identify 
contributions of metabolism from different cellular compartments. 
In a simple one-compartment model one would expect equal 
labelling patterns for metabolites such as lactate and alanine 
derived from pyruvate as a common precursor. Label 
incorporation in these metabolites, further down-stream, should 
also be reflected by labelling in glutamate and aspartate. In our 
model-free analysis of label incorporation in MCF7 cells, we 
observe equal label incorporation ratios between C2 and C3 for 
pyruvate and lactate, whereas glycolytically derived alanine is 
different. This effect is more pronounced for glutamate 
isotopomers. It is well-known that lactate is produced in the 
cytosol, whereas glutamate with this labelling pattern is 
exclusively synthesized in mitochondria. Alanine, on the other 
hand, can be synthesized from pyruvate in the cytosol as well as 
in mitochondria. These results can potentially be interpreted as 
alanine being preferentially synthesized inside mitochondria using 
predominantly PPP derived pyruvate. In combination with 
genetically modified cells (e.g. mitochondrial pyruvate carrier 
knock-outs) it should be possible to decipher such pathway 
contributions. The tools described here, which the authors 
distribute via NMRLab and MetaboLab[31,32], are uniquely qualified 
to describe metabolic pathways contributions in mammalian cells 
in a quantitative manner.   
In conclusion, we present a model-free metabolic analysis 
incorporating quantitative NMR and MS data to obtain isotopomer 
contributions in 13C-labelled breast cancer cells. Joint NMR/MS 
analysis leads to highly accurate and precise data that can be 
interpreted in the context of metabolic pathway analysis. 
Experimental Section 
MCF7 breast cancer cells were grown in the presence of [1,2-13C2]-D-
glucose (Sigma-Aldrich) for 8h and subsequently extracted using a 
modified Blye-Digher extraction (see Supplementary Material for details). 
For NMR, samples were dissolved in 100mM phosphate buffer at pH 7.0. 
The NMR analysis was carried out using 1H-13C-HSQC spectra acquired 
at 600MHz with 8192 complex increments to resolve 13C-multiplets. In 
order to reduce acquisition times only 2048 data points were sampled non-
uniformly. NMR spectra were reconstructed using compressed sensing[33] 
and NMRpipe[34] software. 
For GC-MS, samples were run using a 7890A gas chromatograph coupled 
with an Agilent  5975C mass spectrometer and a HP-5 capillary column.  
More details are presented in the supporting information. 
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